Arvinas (NASDAQ:ARVN) leads protein degradation innovation, contributing to the growth of biotech in the nasdaq composite.

Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, ...

ARV-102 is an oral, brain-penetrant investigational PROTAC designed to degrade LRRK2, which is a large, multidomain scaffolding kinase. Increased activity, scaffolding, and expression of LRRK2 have ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has ...

University of Pittsburgh School of Medicine scientists have developed drug candidates that early tests suggest could reverse HIV’s ability to escape detection by the immune system. The team’s research ...

Immune checkpoint molecule expression measured using circulating cell-free RNA isolated from the blood of metastatic prostate cancer patients. Interim analysis of a prospective randomized trial of ...

Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...

Proteolysis Targeting Chimeras (PROTACs) are a novel approach for degrading target proteins. Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as ...

New York, USA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight DelveInsight’s PROTAC Market Insights ...